{"id":"dexloxiglumide","rwe":[{"pmid":"40569649","year":"2025","title":"Drug Solubility in Human Colonic Fluids and Comparison to Small Intestinal and Simulated Fluids.","finding":"","journal":"Molecular pharmaceutics","studyType":"Clinical Study"},{"pmid":"27590736","year":"2016","title":"Dexloxiglumide for the treatment of constipation predominant irritable bowel syndrome.","finding":"","journal":"Expert opinion on pharmacotherapy","studyType":"Clinical Study"},{"pmid":"26548544","year":"2015","title":"New pharmacological treatment options for irritable bowel syndrome with constipation.","finding":"","journal":"Expert opinion on emerging drugs","studyType":"Clinical Study"},{"pmid":"26416485","year":"2016","title":"Effect of selective CCK1 receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders.","finding":"","journal":"Journal of gastroenterology and hepatology","studyType":"Clinical Study"},{"pmid":"24685436","year":"2014","title":"Mapping glucose-mediated gut-to-brain signalling pathways in humans.","finding":"","journal":"NeuroImage","studyType":"Clinical Study"}],"tags":[{"label":"dexloxiglumide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cholecystokinin receptor type A","category":"target"},{"label":"CCKAR","category":"gene"},{"label":"Active","category":"status"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"d-loxiglumide","offLabel":[],"synonyms":["dexloxiglumide","D-Loxiglumide"],"timeline":[],"approvals":[],"brandName":"D-Loxiglumide","ecosystem":[],"mechanism":{"target":"Cholecystokinin receptor type A","targets":[{"gene":"CCKAR","source":"DrugCentral","target":"Cholecystokinin receptor type A","protein":"Cholecystokinin receptor type A"}],"modality":"Small Molecule","drugClass":"dexloxiglumide","explanation":"Imagine your body has a system to control digestion. Dexloxiglumide helps by blocking a specific receptor that sends signals to slow down digestion. This can help with conditions related to digestive issues, but more research is needed to confirm its effectiveness.","oneSentence":"Dexloxiglumide works by binding to the cholecystokinin receptor type A, which is involved in regulating digestive processes.","technicalDetail":"Dexloxiglumide acts as a selective antagonist of the cholecystokinin receptor type A (CCK-A), which is a G protein-coupled receptor involved in the regulation of pancreatic enzyme secretion and gallbladder contraction."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/834","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DEXLOXIGLUMIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEXLOXIGLUMIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:37:03.808196","biosimilars":[],"competitors":[{"drugName":"ceruletide","drugSlug":"ceruletide","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"paclitaxel","drugSlug":"paclitaxel","fdaApproval":"1992-12-29","patentExpiry":"Sep 4, 2032","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"sincalide","drugSlug":"sincalide","fdaApproval":"1976-07-21","patentExpiry":"Apr 20, 2038","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"dexloxiglumide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ceruletide","brandName":"ceruletide","genericName":"ceruletide","approvalYear":"","relationship":"same-target"},{"drugId":"paclitaxel","brandName":"paclitaxel","genericName":"paclitaxel","approvalYear":"1992","relationship":"same-target"},{"drugId":"sincalide","brandName":"sincalide","genericName":"sincalide","approvalYear":"1976","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT00303264","phase":"PHASE2","title":"The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2006-05","conditions":["Dyspepsia"],"enrollment":48,"completionDate":"2007-08"},{"nctId":"NCT00220090","phase":"PHASE3","title":"DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)","status":"COMPLETED","sponsor":"Rottapharm","startDate":"2003-07","conditions":["Irritable Bowel Syndrome"],"enrollment":0,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"69DY40RH9B","CHEBI":"CHEBI:135747","INN_ID":"6782","UMLSCUI":"C0533979","ChEMBL_ID":"CHEMBL550781","DRUGBANK_ID":"DB04856","PUBCHEM_CID":"65937","IUPHAR_LIGAND_ID":"889","MESH_SUPPLEMENTAL_RECORD_UI":"C103490"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.2 hours","clearance":"3.7 mL/min/kg","bioavailability":"48%","fractionUnbound":"0.024%","volumeOfDistribution":"0.18 L/kg"},"publicationCount":48,"therapeuticAreas":["Gastroenterology"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Aug 4","pmid":"40569649","title":"Drug Solubility in Human Colonic Fluids and Comparison to Small Intestinal and Simulated Fluids.","journal":"Molecular pharmaceutics"},{"date":"2016 Oct","pmid":"27590736","title":"Dexloxiglumide for the treatment of constipation predominant irritable bowel syndrome.","journal":"Expert opinion on pharmacotherapy"},{"date":"2015","pmid":"26548544","title":"New pharmacological treatment options for irritable bowel syndrome with constipation.","journal":"Expert opinion on emerging drugs"},{"date":"2016 Feb","pmid":"26416485","title":"Effect of selective CCK1 receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders.","journal":"Journal of gastroenterology and hepatology"},{"date":"2014 Aug 1","pmid":"24685436","title":"Mapping glucose-mediated gut-to-brain signalling pathways in humans.","journal":"NeuroImage"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"D-Loxiglumide is a small molecule that acts as an antagonist to the cholecystokinin A receptor. It is classified as an antagonist and works by blocking the cholecystokinin A receptor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}